CN116583502A - 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 - Google Patents
二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 Download PDFInfo
- Publication number
- CN116583502A CN116583502A CN202180074263.5A CN202180074263A CN116583502A CN 116583502 A CN116583502 A CN 116583502A CN 202180074263 A CN202180074263 A CN 202180074263A CN 116583502 A CN116583502 A CN 116583502A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- certain embodiments
- alkenyl
- alkynyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074216P | 2020-09-03 | 2020-09-03 | |
| US63/074216 | 2020-09-03 | ||
| PCT/US2021/049021 WO2022051596A1 (en) | 2020-09-03 | 2021-09-03 | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116583502A true CN116583502A (zh) | 2023-08-11 |
Family
ID=78078375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180074263.5A Pending CN116583502A (zh) | 2020-09-03 | 2021-09-03 | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12503475B2 (https=) |
| EP (1) | EP4208444A1 (https=) |
| JP (1) | JP7840517B2 (https=) |
| CN (1) | CN116583502A (https=) |
| TW (1) | TW202227397A (https=) |
| WO (1) | WO2022051596A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| EP4065585B1 (en) | 2019-11-25 | 2025-08-20 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| CN116583502A (zh) | 2020-09-03 | 2023-08-11 | 欧瑞夏治疗有限公司 | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| EP4486445A1 (en) * | 2022-03-01 | 2025-01-08 | Centessa Pharmaceuticals (UK) Limited | Bicyclic-heterocycle derivatives and related uses |
| CN115124410B (zh) * | 2022-08-13 | 2024-06-04 | 上海珂华生物科技有限公司 | 一种2-氟-4-羟基苯甲醛的制备方法 |
| EP4611745A1 (en) | 2022-10-31 | 2025-09-10 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2024128305A1 (ja) | 2022-12-16 | 2024-06-20 | 第一三共株式会社 | ２－アザビシクロ［３．１．１］ヘプタン化合物 |
| EP4719397A1 (en) | 2023-06-02 | 2026-04-08 | Takeda Pharmaceutical Company Limited | Use of an orexin 2 receptor agonist for improving respiratory function during sleep |
| WO2025124698A1 (en) | 2023-12-12 | 2025-06-19 | Idorsia Pharmaceuticals Ltd | Aryl sulfone and sulfanone derivatives as orexin receptor modulators |
| TW202542165A (zh) | 2023-12-19 | 2025-11-01 | 瑞士商愛杜西亞製藥有限公司 | 大環食慾素激動劑 |
| WO2025137359A1 (en) * | 2023-12-20 | 2025-06-26 | Eisai R&D Management Co., Ltd. | Assay methods to identify a disease |
| GB202404750D0 (en) | 2024-04-03 | 2024-05-15 | Bial Portela & Ca Sa | Orexin receptor agonists |
| WO2025229495A1 (en) * | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2026019302A1 (ko) * | 2024-07-18 | 2026-01-22 | (주)셀트리온 | 신규한 오렉신 2 수용체 작용제 및 이의 용도 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102471314A (zh) * | 2009-07-15 | 2012-05-23 | 罗达制药股份公司 | 适合于特别是睡眠障碍和药物成瘾的治疗的螺氨基化合物 |
| WO2013092893A1 (en) * | 2011-12-21 | 2013-06-27 | Rottapharm Spa | Chemical compounds |
| CN111051295A (zh) * | 2017-08-03 | 2020-04-21 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| WO2020167706A1 (en) * | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| CN113395993A (zh) * | 2019-01-31 | 2021-09-14 | 武田药品工业株式会社 | 杂环化合物及其用途 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| JP5454943B2 (ja) | 2007-04-12 | 2014-03-26 | ジョイアント ファーマスーティカルズ、インク． | 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体 |
| WO2009070689A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease |
| US8871794B2 (en) | 2008-06-04 | 2014-10-28 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| WO2011073376A1 (en) | 2009-12-18 | 2011-06-23 | Euroscreen S.A. | Pyrrolidine or thiazolidine carboxylic acid derivatives, pharmaceutical composition and methods for use in treating metabolic disordersas as agonists of g- protein coupled receptor 43 (gpr43) |
| GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| US9309236B2 (en) | 2011-10-05 | 2016-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | PI-kinase inhibitors with broad spectrum anti-infective activity |
| CN105916500A (zh) | 2013-11-27 | 2016-08-31 | 欧洲筛选有限公司 | 用于治疗炎性疾病的化合物、药物组合物和方法 |
| SG11201700851WA (en) | 2014-08-05 | 2017-03-30 | Alios Biopharma Inc | Combination therapy for treating a paramyxovirus |
| WO2016021629A1 (ja) | 2014-08-06 | 2016-02-11 | 塩野義製薬株式会社 | ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体 |
| LT3984994T (lt) | 2016-02-04 | 2024-10-10 | Takeda Pharmaceutical Company Limited | Pakeistas piperidino junginys kaip 2 tipo oreksino agonistas narkolepsijai gydyti |
| JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US11059780B2 (en) | 2017-03-08 | 2021-07-13 | Takeda Pharmaceutical Company Limited | Substituted pyrrolidine compound and use thereof |
| WO2019027069A1 (ko) | 2017-08-03 | 2019-02-07 | (주)상아프론테크 | 연료전지 전해질 강화막 및 이의 제조방법 |
| JP7339250B2 (ja) | 2018-06-29 | 2023-09-05 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| US12071434B2 (en) | 2018-12-12 | 2024-08-27 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3896060B1 (en) | 2018-12-12 | 2023-08-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AU2020346456A1 (en) | 2019-09-13 | 2022-04-14 | Takeda Pharmaceutical Company Limited | TAK-925 for use in treating narcolepsy |
| KR20220062361A (ko) | 2019-09-13 | 2022-05-16 | 다케다 야쿠힌 고교 가부시키가이샤 | 과도한 졸림의 치료를 위한 오렉신 2 수용체 효능제의 용도 |
| JPWO2021065893A1 (https=) | 2019-09-30 | 2021-04-08 | ||
| EP4065585B1 (en) | 2019-11-25 | 2025-08-20 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| ES3061443T3 (en) | 2019-11-27 | 2026-04-01 | Sumitomo Pharma Co Ltd | Cycloalkyl urea derivative |
| US20210200298A1 (en) | 2019-12-30 | 2021-07-01 | Advanced Micro Devices, Inc. | Long-idle state system and method |
| JP7811578B2 (ja) | 2020-09-03 | 2026-02-05 | センテッサ ファーマシューティカルズ （ユーケー） リミテッド | 中環状または大環状ベンジル置換複素環誘導体およびオレキシン－２受容体アゴニストとしてのそれらの使用 |
| CN116583502A (zh) | 2020-09-03 | 2023-08-11 | 欧瑞夏治疗有限公司 | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| WO2023017180A1 (en) | 2021-08-13 | 2023-02-16 | Orexia Therapeutics Limited | Peptide derivatives and related uses as orexin agonists |
| JP2025507852A (ja) | 2022-03-01 | 2025-03-21 | センテッサ ファーマシューティカルズ （ユーケー） リミテッド | 中環状または大環状ベンジル置換複素環誘導体および関連の使用 |
| EP4486445A1 (en) | 2022-03-01 | 2025-01-08 | Centessa Pharmaceuticals (UK) Limited | Bicyclic-heterocycle derivatives and related uses |
-
2021
- 2021-09-03 CN CN202180074263.5A patent/CN116583502A/zh active Pending
- 2021-09-03 EP EP21786660.7A patent/EP4208444A1/en active Pending
- 2021-09-03 TW TW110132883A patent/TW202227397A/zh unknown
- 2021-09-03 WO PCT/US2021/049021 patent/WO2022051596A1/en not_active Ceased
- 2021-09-03 US US18/024,216 patent/US12503475B2/en active Active
- 2021-09-03 JP JP2023515057A patent/JP7840517B2/ja active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102471314A (zh) * | 2009-07-15 | 2012-05-23 | 罗达制药股份公司 | 适合于特别是睡眠障碍和药物成瘾的治疗的螺氨基化合物 |
| WO2013092893A1 (en) * | 2011-12-21 | 2013-06-27 | Rottapharm Spa | Chemical compounds |
| CN111051295A (zh) * | 2017-08-03 | 2020-04-21 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| CN113395993A (zh) * | 2019-01-31 | 2021-09-14 | 武田药品工业株式会社 | 杂环化合物及其用途 |
| WO2020167706A1 (en) * | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202227397A (zh) | 2022-07-16 |
| JP2023540344A (ja) | 2023-09-22 |
| WO2022051596A8 (en) | 2022-04-07 |
| WO2022051596A1 (en) | 2022-03-10 |
| US12503475B2 (en) | 2025-12-23 |
| JP7840517B2 (ja) | 2026-04-06 |
| EP4208444A1 (en) | 2023-07-12 |
| US20230271973A1 (en) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116583502A (zh) | 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途 | |
| CN116635393A (zh) | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 | |
| RU2679914C1 (ru) | Конденсированные трициклические производные имидазола в качестве модуляторов активности tnf | |
| IL275058B2 (en) | Sulfonylurea derivatives as modulators of the NLRP3 inflammasome | |
| WO2025072451A1 (en) | Ras-pi3k inhibitors for the treatment of cancer and immunological diseases | |
| JP7207634B2 (ja) | Ｐ２ｘ３及び／又はｐ２ｘ２／３受容体アンタゴニスト、それを含む医薬組成物及びその使用 | |
| TW202237597A (zh) | 新型egfr降解劑 | |
| TW202317092A (zh) | Ｋｉｆ１８ａ之吲哚啉抑制劑 | |
| CN119156375A (zh) | 双环杂环衍生物和相关用途 | |
| CN119110802A (zh) | 中环或大环苄基取代的杂环衍生物和相关用途 | |
| WO2022207935A1 (en) | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists | |
| JP2022519301A (ja) | Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体及び疾患の処置におけるそれらの使用 | |
| AU2013253541A1 (en) | Quinazolinedione derivative | |
| WO2024026424A1 (en) | Quinazolinone derivatives as and related uses | |
| WO2019189555A1 (ja) | 複素環化合物 | |
| CN111902401B (zh) | 受体抑制剂、包含其的药物组合物及其用途 | |
| JP2025530793A (ja) | Ｅｇｆｒ阻害剤及びその使用 | |
| WO2021228216A1 (zh) | 可用作RORγ调节剂的联芳基类化合物 | |
| CN113773251A (zh) | 可用作RORγ调节剂的苯胺类化合物 | |
| HK40062607A (en) | BIARYL COMPOUNDS USEFUL AS RORγ MODULATORS | |
| HK40059280A (en) | ANILINE COMPOUNDS USEFUL AS RORγMODULATORS | |
| EP4531849A1 (en) | Heterocyclic pad4 inhibitors | |
| EA052303B1 (ru) | Средне- или макроциклические производные бензилзамещенного гетероцикла и связанные с ними применения | |
| HK40118125A (zh) | Egfr抑制剂和其用途 | |
| HK40032239B (en) | Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information |
Address after: Cheshire Applicant after: Sentesa Pharmaceuticals (Oresa) Co.,Ltd. Address before: London Applicant before: Ouruixia Treatment Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240218 Address after: Cheshire Applicant after: Sentesa Pharmaceuticals (UK) Ltd. Country or region after: United Kingdom Address before: Cheshire Applicant before: Sentesa Pharmaceuticals (Oresa) Co.,Ltd. Country or region before: United Kingdom |
|
| TA01 | Transfer of patent application right |